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Abstract
HIV is the virus that causes AIDS. Its infection occurs by binding to CD4+ receptor and chemokine receptor 5 
(CCR5). Recent studies have shown that reasons for progression and non-progression are multi factorial and may 
involve genetic, virological and immunological factors that influence HIV disease progression in various ways.
Chemokine receptors act as important co receptors mediating the entry of the human immunodeficiency virus type 
1 (HIV-1) into susceptible cells. The Δ32 mutation at the CCR5 locus is a well-studied example of natural selection 
acting in humans. Homozygous carriers of the Δ32 mutation are resistant to HIV-1.
The aim of the present study was to assess the frequency of CCR5-Δ32 (Chemokine receptor delta 32 allele) in 
HIV-1 untreated individuals who visited Gondar university teaching hospital.
3 ml blood samples of fifty HIV-1 untreated seropositive individual and equal numbers of age and sex match 
seronegative individual who are exposed and uninfected were collected using EDTA coated vacutenous tubes. DNA 
from 1 ml blood samples was isolated using phenol-chloroform method.
Specially designed primers, both forward and reverse was used to amplify the alleles of CCR5 using PCR 
(Polymerase chain reaction). Desirable data regarding study subjects were collected by using specifically designed 
questioner. SPSS 16 and EPI-info version 3.2 were used to analyze the data.
The frequency of the homozygous CCR5 mutant allele was zero in the study population and there was statistically 
no significance difference between the frequency of the heterozygous allele among cases and controls. There was no 
homozygous mutant allele both in cases and controls in the present study. This may be due to small sample size and 
thus another study on the same population with large sample size is warranted to further confirm the result.
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Introduction
Background information
HIV (Human Immunodeficiency Virus) is the virus that causes 
AIDS. This virus may be passed from one person to another with 
infected blood, semen, or vaginal secretions come in contact with an 
uninfected person’s broken skin or mucous membranes. In addition, 
infected pregnant women can pass HIV to their baby during pregnancy 
or delivery, as well as through breast-feeding [1].
Acquired immunodeficiency syndrome (AIDS) is a progressive 
deterioration of the immune status of the individual. It is characterized 
by the progressive depletion of the CD4 T lymphocyte, which 
represents a major target of viral infection by the causative human 
immunodeficiency virus (HIV).The continuing rise in the population of 
people living with HIV reflects the combined effects of continued high 
rates of new HIV infections and the beneficial impact of antiretroviral 
therapy [2].
United Nations Joint Programme on HIV/AIDS indicated on the 
Global AIDS epidemic 2012 reports that despite variances between the 
rise and decline among infected people across the world, globally 34.0 
million [31.4 million–35.9 million] people were living with HIV at the 
end of 2011. An estimated 0.8% of adults aged 15–49 years world wide 
are living with HIV, although the burden of the epidemic continues to 
vary considerably between countries and regions. Sub-Saharan Africa 
remains most severely affected, with nearly 1 in every 20 adults (4.9%) 
living with HIV and accounting for 69% of the people living with 
HIV worldwide. Although the regional prevalence of HIV infection is 
nearly 25 times higher in sub-Saharan Africa than in Asia, almost 5 
million people are living with HIV in South, South-East and East Asia 
combined. After sub-Saharan Africa, the region’s most heavily affected 
are the Caribbean and Eastern Europe and Central Asia, where 1.0% of 
adults were living with HIV in 2011 [3].
The Federal Democratic Republic of Ethiopia joined UN Member 
States in June 2006 at the UN General Assembly to issue the Political 
Declaration on HIV/AIDS, which included a commitment to move 
towards the goal of universal access to HIV prevention, treatment, 
care and support by 2010. Since that commitment was made, Ethiopia 
has updated its planning framework with ambitious targets to achieve 
universal access, and it has launched a “Millennium AIDS Campaign 
that has catalyzed more rapid scale up of key prevention and treatment 
programs. Data obtained in 2005 from the Demographic and Health 
Survey (DHS) indicate that the epidemic may be less severe, less 
generalized and more heterogeneous than previously believed. 
A careful assessment of data gathered over the last six years suggests 
that the epidemic has stabilized, with adult HIV prevalence estimated 
at 2.2% in 2003/04 and 2.1% in 2006/07. The rural epidemic appears to 
be relatively widespread but heterogeneous, with most regions having 
a relatively low prevalence of HIV, but a few demonstrating adult 
prevalence greater than 5%. In general, HIV incidence is leveling off 
after declining over the last few years (1996-2001) [4]. Country HIV 
prevalence estimates hinge on assumptions such as representativeness 
of surveillance systems. Until recently, Ethiopia had a national HIV 
prevalence estimate of 9.3% among persons aged 15–49 years and 
ranked third in terms of total persons infected. In 2002, this estimate 
has been adjusted to 6.4% [5].
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The natural history of HIV-1 infection varies considerably from 
one individual to another, with some individuals progressing to 
AIDS rapidly after primary infection, while others remain clinically 
asymptomatic with no evidence of immune dysfunction. Recent studies 
have shown that reasons for progression and non-progression are multi 
factorial and may involve genetic, virological and immunological 
factors that influence HIV disease progression in various ways. The 
virus has varied impacts on the immune cells. These include direct viral 
killing of the infected cells (microphages and microglia), apoptosis and 
killing of the CD4+ T-cells [6].
Human immunodeficiency virus-1 infection
Human Immune deficiency Virus-1 (HIV-1) invades immune 
cells. Because macrophage and T-cell possess CD4 proteins that are 
why the virus easily invades them [7] .It was the time since 1984 CD4 
is the components of HIV-1 receptor it was discovered but not to be 
sufficient to allow HIV-1 to infect cells [8]. 
For attachment and subsequent entry of the virus to the target cells 
requires both the CD4 proteins and one of the main co receptors (CCR5 
and CXCR4) or minor co receptor like CCR2 and CCR3 [9]. The main 
step in HIV-1 replication cycle is attachment and entry into target cells 
and this is mediated by binding of viral glycoprotein gp 120 to CD4 
proteins expressed on target cells [10].
Viral replication
The first step in the reproductive cycle of HIV is the virus attaching 
to a susceptible host cell. This interaction is mediated through the host-
cell CD4 antigen, which serves as a receptor for the virus by binding 
the gp120 glycoprotein on the outer envelope of HIV. T helper cells are 
the main target for HIV infection, because they express high numbers 
of CD4 molecules on their cell surface and bind the virus with high 
affinity [11]. Other cells such as macrophages, monocytes, dendritic 
cells, Langerhans cells and microglial brain cells can also be infected 
with HIV, because they have some surface CD4. HIV viruses that 
preferentially infect T cells are known as T-tropic or X4 strains, while 
those strains that can infect both macrophages and T cells are called 
M-tropic or R5 strains. Entry of HIV into the host cells to which it has 
attached requires an additional binding step involving co receptors that 
promote fusion of the HIV envelope with the plasma cell membrane. 
These co receptors belong to a family of proteins known as chemokine 
receptors, whose main function is to direct white blood cells to sites of 
inflammation. The chemokine receptor CXCR4 is required for HIV to 
enter T lymphocytes, while the chemokine receptor CCR5 is required 
for entry into macrophages. Binding of the co receptors allows for HIV 
entry by inducing a conformational change in the gp41 glycoprotein, 
which mediates fusion of the virus to the cell membrane. After fusion 
occurs, the viral particle is taken into the cell and uncoating of the 
particle exposes the viral genome [12].
Action of the enzyme reverse transcriptase produces complementary 
DNA from the viral RNA. This DNA becomes integrated into the host 
cell’s genome and is called a provirus. The provirus can remain in a 
latent state for a long period of time, during which viral replication does 
not occur. Eventually, expression of the viral genesis induced when the 
infected host cell is activated by binding to antigen or by exposure to 
cytokines. Viral DNA within the cell nucleus is then transcribed into 
genomic RNA and messenger RNA (mRNA), which are transported to 
the cytoplasm. Translation of mRNA occurs, with production of viral 
proteins and assembly of viral particles. The intact virions bud out from 
the host cell membrane and acquire their envelope during the process. 
These viruses can then proceed to infect additional host cells. Viral 
replication occurs to the greatest extent in antigen-activated T helper 
cells. Because viral replication occurs very rapidly, and the reverse 
transcriptase enzyme lacks proofreading activity, genetic mutations 
commonly occur, producing distinct isolates that exhibit antigenic 
variation. These isolates can vary in their susceptibility to the host’s 
immune responses [13].
Despite multiple sexual exposures to HIV-1 virus, some individuals 
remain HIV-1 seronegative. The mechanisms underlying this resistance 
remain still unclear, although a multi factorial pathogenesis can be 
hypothesized. Also, several genetic factors have been related to HIV-
1 as the etiologic agent of AIDS, the chemokine receptor CCR5 was 
identified as one of the major co receptors for macrophage tropic virus, 
the key pathogenic strains in vivo [14].
A mutant allele of the βchemokine receptors gene CCR5 bearing a 
32 BP deletion (denoted ∆CCR5) which protects cell invasions by the 
primary transmitting strains of HIV-1 has recently been characterized 
.The denoted ∆32 mutation at the CCR5 locus is a well -studied -example 
of natural selection acting in humans .The mutation is found principally 
in Europe and Western Asia, with higher frequencies generally in north 
Europe [15].
Homozygous carriers of ∆32 mutations are resistance to HIV-1 
infection because the mutation prevents functional expression of the 
CCR5 chemokine receptors normally used by HIV-1 to enter CD4T 
cells. More recently, additional polymorphisms in the CCR5 promoter 
have been identified, some of which appear to have clinical relevance 
to HIV-1 disease. It is plausible that these promoter mutations may 
also affect the level of expression of CCR5, which is known to vary 
even among individuals with wild-type CCR5-coding allele. To date, 
however, increased promoter activity has been demonstrated only for 
the 59029-A allele [16]. Polymorphisms with single nucleotide changes 
have been described at position 59029, 59353, 59356 and 59402. In one 
study, a CCR5 promoter variant haplotype with a specific combination 
of polymorphism (defined as p1 with 59353-C 59356-C,and 59402-
A) was associated with acceleration of disease progression [17]. In 
contrast, the 59353-C polymorphism was associated with delayed 
progression to immune suppression but not to AIDS. The effects of 
these 2 polymorphisms were analyzed in a recent study that confirmed 
an association between 59029-A and more rapid disease progression 
and conclude that 59353-C homozygous individuals were significantly 
under represented among long term non progresses [18].
Significance and the anticipated output
Several natural polymorphisms in the genes for human CXCR4 
and CCRS chemokine receptor have been associated with HIV-1 
progression to AIDS [19]. 
As far as our knowledge goes this is the first study in Ethiopia, 
therefore, this study will fill that gap.
Objective of the Study
General objectives
The general objective of this study was to compare the frequency 
of CCR5 allele among people who visited Gondar university teaching 
hospital and other non Ethiopian population. 
Specific objectives 
The specific objectives of this study were: 
•	 Determined and compare the frequency of the alleles among 
cases and controls.
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•	  Determined the role of CCR5-∆32 allele in response to disease 
progression 
•	 Analyzed the number of exposed and uninfected individuals 
who visited Gondar University teaching hospital, if any
The CCR5 delta32 variant and AIDS
A common genetic variant in the coding region of the CCR5 
structural gene involves a 32 base pair deletion (CCR5-_32) that shifts 
the open reading frame to create a truncated protein. This protein fails 
to reach the cell surface in individuals homozygous for the variant [20]. 
The pathogenic mechanisms that underlie HIV-1 infection are 
complex and highly variable and depend on the interplay between 
numerous viral and host factors [21]. 
When HIV binds to host cells, it uses the CD4 receptor on the surface 
of host immune cells together with a co receptor, mainly the CCR5 and 
CXCR4 chemokine receptors. CCR5 is a host–cell chemokine receptor, 
which is also used as a co receptor by R5 strains of HIV that are generally 
acquired during sexual transmissions .Homozygous mutations for this 
32 bp deletion offer almost complete protection from HIV infection 
and heterozygous mutations are associated with lower pre-AIDS viral 
load and delayed progressions to AIDS. CCRS∆32 generally is found 
in population of Europe decent, with allelic frequencies ranging from 
0 to 0.29. Africa and Asian population studied outside the united 
states or Europe appear to be short of the CCR5∆32 allele, with allelic 
frequencies less than 0.29 [22].
Genetic association analysis of over 10,000 individuals at risk for 
HIV infection has shown that CCR5-_32/_32 homozygote’s completely 
resist infection by primary R5-tropic HIV strains [23], although there are 
a few reports of homozygote’s who have become infected with the later 
stage X4 strains, likely because the virus has surpassed the requirement 
for CCR5 by utilizing CXCR4 instead [24]. It may be important that rare 
homozygote’s who harbor X4 strains have a lower HIV viral load (i.e., 
concentration in blood) than do CCR5+/_32 orCCR5+/+ individuals 
infected with R5 or R5X4 viruses [25]. This differential may reflect 
limits on the ability of CXCR4+ cells to replicate HIV maximally in vivo. 
It could explain, at least partially, why R5 viruses are so favored in early 
infection, estimated at 90–95% of primary infections [26].
A limited capacity of CXCR4+CCR5– cells to replicate HIV may 
also explain the shift from X4 to R5 predominance observed in two 
CCR5-+/+ individuals soon after primary infection, since an excess 
of virus production from CCR5+CD4+-activated lymphocytes would 
select in vivo for a preponderance of R5 HIV variants, although other 
explanations are also possible [27].
In the past, there were several attempts to control HIV-1 infection 
by means of allergenic stem cell transplantation without regard to the 
donor’s CCR5delta 32 status, but these efforts were not successful. Host 
genetics impact HIV infection at two main points: (i) Cell virion fusion, 
mediated primary by the chemokine receptors CCR5 and CXCR4 and 
their natural ligands and (ii) the host immune response, mediated by 
human leukocyte antigen (HLA) molecules [28]. Although the median 
interval between HIV-1 infection and the development of the Acquired 
Immune Deficiency Syndrome(AIDS) in adults is 10 to 11 years, some 
infected persons rapidly progress to AIDS is less than 5 years. Still other 
remain asymptomatic without evidence of immunologic decline for 
more than 6 years .polymorphisms of the gene controlling these two 
pathways have been extensively studied and multiple genetic allele that 
have been found to correlated with either delayed or accelerated disease 
progression have been reported [29]. Studies of the effect of host genes 
on susceptibility to HIV infection were facilated by the identification of 
persons who were per-sistansely exposed to HIV but remain uninfected 
[30].
The recently characterized chemokine receptor gene CCR5 and 
its most frequent mutation (∆32) have become the objects of intense 
interest since their roles in the entry of HIV -1 into target cells were 
identified. Homozygous for a 32 bp deleted allele in the CCR5 gene 
protects adults from HIV-1 infection following blood or sexual exposure 
.Several large studies of the effect CCR5 genotypes on the course of HIV 
disease have been published [31]. Dean et al. examined the course of 
HIV (time to AIDS) in several U.S population with different exposure 
to HIV (homo sexual, intravenous drug user, persons with hemophilia) 
and found that persons with one copy of the deleted CCR5 gene had 
a delayed approximately 2 years longer progressions to AIDS when 
compared with those with the homozygous wild type genotype [32]. 
Heterozygous for a ∆32 deletion (CCR5-wt/∆32) are not protected 
against HIV-1 infection but manifests slow progressions to HIV-1 and 
AIDS end points [33]. Some of the polymorphisms in the promoter 
region have been found to raise the risk of prenatal transmissions to 
HIV-1 [34]. A G to A substitution at position 180 affects the gene that 
codes for CCR2, a minor HIV-1 co-receptor. This mutation causes 
substitutions of isolecucine to valine at position 64 (designed as CCR2-
64I) which eventually slows down progressions in adults [35]. Similar 
findings are reported [36] in Caucasian HIV-positive homosexual men. 
Another study of HIV–positive homosexual did not find such a striking 
effect of heterozygosis, although progressions to AIDS were again 
slowed [37]. Though the result was not similar to Caucasian population 
a study in Kenya has demonstrated that children with homozygous 
mutant allele were less exposed to vertical transmissions of HIV-1 from 
their mother. A study in South Africa demonstrated similar result [38].
Materials and Method 
The study design was experimental and cross sectional. 
Collection of sample
Peripheral blood samples were obtained from both cases and 
controls. For this case control study fifty blood samples from HIV-1sero 
positive individuals, age and sex matched exposed but seronegative 
individuals were taken from Gondar university teaching hospital from 
May, 2012–July, 2012.The blood samples of all this study subjects was 
collected with EDTA coated non-vacutenous tubes from these hospitals. 
Essential questioner regarding, age, sex, CD4 counts were filled by 
the concerned clinician. The blood samples were transported from 
these hospitals to Gondar University, department of biotechnology, 
molecular biology laboratory by ice cube box. The blood samples then 
were stored in deep freeze until processing. 
Isolation of genomic DNA 
Genomic DNA was isolated from EDTA anti-coagulated peripheral 
blood by phenol-chloroform extraction method. 
Protocol
1.  Frozen blood samples were thawed. 
2. 1 ml of blood was added to 2.5 ml eppendorff. Then 1 ml of 0.8 
M 1x saline sodium chloride buffer was added and content was 
mixed. The mixture was centrifuged at 10,000 rpm for 5 min in 
cooling centrifuge at 4ºC. 
3. 1 ml of the supernatant was discarded into disinfectant. 
4. To the eppendorff 1 ml of 1x SSC buffer was added, it was 
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Vortexed and centrifuged as above for 5 min. Then all the 
supernatant was removed. 
5. 375 µl of 0.2 M sodium acetate was added to each pellet and 
briefly vortexed. It was followed by the addition of 250 µl of 
Sodium dodecyl sulphate and incubated for 1 h at 55ºC. 
6. 120 µl mixture of phenol (60 µl)/ chloroform (57.6 µl)/isoamyl 
alcohol (2.4 µl) was added to each eppendorff and then vortexed 
for 30 s. The sample was centrifuged for five minutes at 10,000 
rpm. 
7. The upper layer was carefully transferred to 1.5 ml 
microcentrifuge tube and 1 ml of cold 100% chilled ethanol was 
added. The mixture was gently mixed to precipitate the DNA. 
8. The tube was kept at -20ºC overnight and then centrifuged at 
5000 rpm for 2 min. 
9. The supernatant was drained and the pellet was dissolved in 
100 µl of tris- EDTA. 
10. It was stored at – 20ºC after cheeking in 0.8% agarose gel.
Agarose gel electrophoresis 
Reagents: 
•	 Agarose 
•	 1x Tris-Acetate (TAE) buffer 
•	 Bromophenol blue 
•	 DNA marker (100 bp) 
Protocol: The protocol for electrophoresis consisted of three steps: 
Preparation of agarose gel: 
1. 25 ml of (1x) TAE buffer was taken in a beaker. 
2. Agarose (0.25 g) was added to this buffer. 
3. The solution was heated to boil (using microwave oven) until all 
the gel particles were dissolved. 
The solution was allowed to cool down to 50-60ºC.
Casting of the horizontal agarose gel:
1. The gel was assembled to casting tray and the comb was 
positioned at its one end. 
2. The agarose solution was poured into the gel tray and kept at 
room temperature. 
3. The comb was carefully removed and the gel replaced in 
electrophoresis chamber. 
4. The chamber was filled with TAE electrophoresis buffer until it 
reached 3-5 mm over the surface of the gel. 
Loading and running DNA in agarose: 
1. DNA (3 µl) was mixed with bromophenol blue in the ratio of 
3:1 and loaded in the wells of the 0.8% agarose gel. 
2. The cathode was connected to the well side of the unit and the 
anode to the other side. 
3. The gel was run 60 V until, the bromophenol blue tracing dye 
migrated near to the other end. 
4. The DNA was observed by staining the gel with ethidium 
bromide (0.5 µg/ml) and viewed under UV transilluminator.
CCR5 allele amplification from human blood genomic DNA 
by PCR
Polymerase chain reaction amplification of CCR5 allele was 
performed on genomic DNA prepared from frozen peripheral blood 
mononuclear cells by phenol chloroform methods. Two primers 
encompassing the 32 bp deletion found in CCR5 Δ32 were used :
The forward primer: TTCATTACACCTGCAGCTCTCATTTTC 
and the reverse primer: CTCACAGCCCTGTGCCTCTTCTTCTC, 
yielding respectively, 184 bp fragment for the wild–type allele (WT) 
and 152 bp fragment for the mutated allele. The PCR amplification was 
carried out in a reaction mixture of 25 μl containing genomic DNA, 5 
Mm MgCl2, 10 mM mixed dNTP (dATP, dCTP, dGTP and dTTP),0.3 
units Taq polymerase, distilled water and 10x PCR buffer. Polymerase 
concentrations and primer sequence are available from the producer 
at Sigma Aldrich by ordering them based on the previous work of 
Micheline et al. and amplified using 96 well PCR thermo cycler.
The PCR amplification was carried out in a reaction mixture of 25 
μl containing genomic DNA, 5 Mm MgCl2, 10 mM mixed dNTP, 0.3 
units Taq polymerase, distilled water and 10x PCR buffer.
The PCR condition for denaturation was set up of 95°C for 10 min, 
followed by 30 cycles of PCR were performed as follow: a denaturation 
step for 1 min at 93°C, annealing step for 1 min at 54°C and an extension 
step for 6 min at 72°C. 
The presence of the wild allele (WT) and heterozygous allele 
were identified by using 100 bp DNA marker by 2% agarose gel 
electrophoresis (Figures 1 and 2). 
Statistical analysis
Essential questioner regarding, age, sex and CD4 count were 
prepared and filled by the concerned clinician. All these variables were 
computed using SPSS version 16. And the relative risk of each allele was 
computed by analyzing odds ratio and p value using EPI info version 
3.2. (Center for disease control and prevention, Atlanta, USA) as per 
the recommendation of the World Health Organization.
Result
In the present study 50 HIV-1 untreated seropositive and equal number 
of exposed and un-infected individuals were included (Table 1).
            1                   2             3                   4                  5 
 
gDNA 
Figure 1: Agarose gel representative picture of genomic DNA extracted from 
cases blood Lan1-5 genomic DNA extracted from cases. 
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As the above table indicated more HIV postive individual are with 
in the age range of 24-30 and the data shows 28% it is more number 
than others. Also, the table indicated more HIV positive individuals sex 
is equal in both male and sex that is in male 25% and also in female 25% 
but in HIV negative individuals were varied that was in female 24% and 
for male 26%.
Centers for Disease Controls classified CD4 as >500, 200-499 and 
<200 by these classification in our study we have seen the association 
between CCR5 delta 32 allele and CD4 (Table 2).
In our case study individuals who have >500 CD4 have six wild 
type and 2 heterozygous, 200-499 have 24 (48%) wild type and 1 
(2%) heterozygous and <200 have 17 (34%) wild type and 0 (0%) 
heterozygous. 
The heterozygous CCR5 genotype showed statistically reduced the 
progressions of HIV-1 with P value 0.041 that means individuals who have 
heterozygous allele can delay the progressions of the viruses (Table 3).
To facilitate rapid genetic screening for the Δ32 allele in Gondar 
university hospital, a PCR-based assay was established using an 
oligonucleotide primer pair designed to identify CCR5 genotypes 
without restriction enzyme analysis and it did not sequence simply we 
have ordered the specific primers to amplified the CCR5 delta 32 allele 
from Sigma Aldrich.
The frequency of homozygous mutant in cases and controls was 
zero. The percentage of heterozygous was 4% in cases and it was 2% in 
controls.
On the other hand the homozygous wild genotype was 98% and 
96% in case and controls respectively.
Discussion
In the present study two groups of Ethiopian were genotyped for 
the CCR5-Δ32 individuals that visited Gondar university teaching 
hospitals to assessed the host genetic susceptibility factors that 
predispose to rate of HIV/AIDS disease progression and resistance to 
develop AIDS in respect to a single gene, CCR5 Δ32 and from the study 
CCR5 Δ32 homozygous gene is totally absent in those population. But 
32 bp deletion mutations among individuals of European Caucasians 
decent indicated that approximately 1 to 3% carries two defective alleles 
and 15 to 30% are heterozygous. Homozygous mutations for this 32 
bp deletion offer almost complete protection from HIV infection, and 
heterozygous mutations are associated with lower pre-AIDS viral load 
and delayed progressions to AIDS [39].
However, in our studied population 0% two defective allele and 2% 
heterozygous allele in case was observed.
A north to south gradient in the delta 32 allele frequency has 
been reported across Europe, with the highest allele frequencies in the 
Finnish and other populations living around the Baltic Sea (10%–20% 
heterozygous;1% homozygous) and the lowest in Sardinia and Greece, 
where the frequency drops to almost zero. The mutation is also seen at 
very low frequencies in populations from Saudi Arabia, Syrian Arab 
Republic, Islamic Republic of Iran, Tunisia, Morocco, Cyprus (Greek), 
India, Pakistan and Asia. It is virtually absent in native populations 
from sub-Saharan Africa and Oceania [40]. 
Our results are consistent with reports in the medical literature 
because our result is close to what is being reported in the Multi-SNP 
analysis of CCR5-CCR2 genes in Ethiopian Jews because those peoples 
are for a long time live in Gondar town which is in our study area 
and150 individuals from Uganda possessed the homozygous Δ32 CCR5 
was zero [41]. This study marks that the distribution of the homozygous 
Δ32 CCR5 allele is similar to that of Uganda these indicated that our 
country Gondar and Uganda people have a little bit similar alleles 
because of the geographical location of those two country is nearby 
each other and both are located in Eastern Africa. Not only in the 
literature in Uganda and Gondar the distribution of the homozygous 
1                2               3                 4                  5 
  
100 bp 
200 bp 
500 bp 
184 bp 
152 bp 
Figure 2: PCR amplified representative agarose gel picture of CCR5 gene 
extracted from cases.
Lane 1. DNA Markers
Lane 2, 4 and 5. 184 bp 
Lane 3. 152 and 184 bp
Age range Control in n (%) Cases in n (%)
17-23 21 (42%) 6 (12%)
24-30 13 (26%) 14 (28%)
31-37 7 (14%) 13 (26%)
38-44 8 (16%) 8 (16%)
45-51 1 (2%) 7 (14%)
52-58 0 (0%) 1 (2%)
59-65 0 (0%) 1 (2%)
Total 100% 100%
 
 Sex 
 
F 24 (48%) 25 (50%)
M 26 (52%) 25 (50%)
Total 100% 100%
Table 1: Demographic characteristics of study subject by age range and sex.
CD4 CCR5wildtype allele n (%) 
 CCR5 Heterozygous 
allele numbers TOTAL
>500 6 (12%) 2 (4%) 8 (16%)
200-499 24 (48%) 1 (2%) 25 (50%)
<200 17 (34%) 0 (0%) 17 (34%)
Total 50 (100%)
Table 2: Demographic characteristics of study subject by association of CD4 and 
CCR5 allele. 
Cases n (%)  Controls n (%)
Wild type 48 (96%) 49 (98%)
Heterozygous 2 (4%) 1 (2%)
Homozygous 0 (0%) 0 (0%)
Table 3: Genotype and allelic frequency of CCR5 allele in cases and controls. 
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mutated gene distribution is zero but also in most East Asian country 
the distribution of these homozygous mutated genes is zero [42]. 
Therefore, this shows that there may be genetic back ground similarity 
between Gondar and Asian country. On the other hand the result of 
this study may hint the genetic back ground differences among Gondar 
population and Europeans. 
Conclusion and Recommendation 
The HIV virus normally enters to a cell via its CCR5. But in people 
with receptors crippled by CCR5 delta 32 mutations, entry of HIV by 
this means is blocked, providing immunity to AIDS for homozygous 
mutant carriers and greatly slowing progress of the disease in 
heterozygous carriers.
In many literature the researchers reported that the CCR5–delta 32 
mutation prevents HIV-1 and slow progressions of HIV-1. However, 
here in this study the frequency of homozygous CCR5-delta 32 is totally 
absent and it can be concluded that the mutated gene in the present 
study is absent or rare. To exactly indicate the frequency of the mutated 
allele and its effect on HIV-1 large sample size with this population 
and other parts of the country shall be considered, has not significant 
difference between the frequency of the heterozygous allele among 
cases and controls in Gondar population. And individuals who have 
heterozygous allele have delayed the progressions of the virus.
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